Mark E Duggan

This inventor holds 79 USPTO granted patents and 6 published patent applications, plus 1 CIPO patent and 8 EPO patents, primarily in Integrin Antagonists (CPC class 5143). Top assignees: Merck + Co., Inc., Scifluor Life Sciences, Inc., Astrazeneca Ab. Active years: 1989-2025.

USPTO Granted Patents = 79 (Patent Applications = 6)

% Patents Active = 70.9

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 3.4

ph-index = 19

Forward Citations = 1,086(Granted Patents)

Forward Citations (Not Self Cited) = 928(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Wynnewood, PA (US) (1989 - 1994)
Narberth, PA (US) (1994 - 2000)
Schwenksville, PA (US) (1993 - 2008)
Harleysville, PA (US) (2006 - 2009)
Wellesley, MA (US) (2007 - 2018)
Tequesta, FL (US) (2018 - 2023)

Company Filing History:

Scifluor Life Sciences, Inc.

Link Medicine Corporation

patents

5. 2 out of 2,405

Merck Sharp + Dohme Corp.

patents

6. 2 out of 5

Ocuterra Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 1989-2025

Loading Chart...

Areas of Expertise:

Integrin Antagonists

Fluorinated Compounds

BACE Inhibitors

Piperazine Derivatives

Androgen Receptor Modulators

Quinolinone Inhibitors

Akt Activity Inhibitors

Aminopyrrolidinone Derivatives

Heteroaryl Piperidine

Benzamide Modulators

Azapine Derivatives

Fluorinated Benzofuran

79 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12497399 - Fluorinated integrin antagonists (2025-12-16),

2. 11685737 - Fluorinated integrin antagonists (2023-06-27),

3. 11046651 - Piperazine substituted azapine derivatives and uses thereof (2021-06-29),

4. 10155758 - Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives (2018-12-18),

5. 10106537 - Fluorinated integrin antagonists (2018-10-23),

6. 10053453 - Compounds and their use as BACE inhibitors (2018-08-21),

7. 9895340 - Fluorinated benzofuran derivatives (2018-02-20),

8. 9802933 - Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives (2017-10-31),

9. 9717729 - Fluorinated integrin antagonists (2017-08-01),

10. 9624189 - Fluorinated benzofuran derivatives (2017-04-18),

11. 9593114 - Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives (2017-03-14),

12. 9556114 - Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives (2017-01-31),

13. 9518053 - Fluorinated integrin antagonists (2016-12-13),

14. 9266884 - Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-y1)-3-arylpropanoic acid derivatives (2016-02-23),

15. 8916133 - Fluorinated 2-amino-4-(benzylamino)phenylcarbamate derivatives (2014-12-23),

Title: Innovations and Achievements of Mark E. Duggan

Introduction

Mark E. Duggan, based in Wellesley, MA, is a notable inventor with an impressive portfolio of 78 patents. His innovative contributions primarily focus on pharmaceuticals, specifically compounds that target various medical conditions. His work reflects a deep commitment to advancing medical science through innovative strategies.

Latest Patents

Among his latest patents is the invention related to "Fluorinated Integrin Antagonists." This invention delves into the synthesis of fluorinated compounds aimed at providing therapeutic solutions for conditions such as macular degeneration, diabetic retinopathy, and related disorders. Additionally, Duggan's patent on "Piperazine Substituted Azapine Derivatives and Uses Thereof" describes compounds that modulate H1 and 5-HT receptors, offering potential treatments for sleep disorders including sleep fragmentation and disturbed sleep.

Career Highlights

Mark's career boasts significant contributions while working with esteemed companies like Merck & Company, Inc. and Scifluor Life Sciences, Inc. His expertise in pharmaceutical innovation has made him a valuable asset in the field.

Collaborations

Throughout his career, Duggan has collaborated with notable individuals, including colleagues such as George D. Hartman and Ben C. Askew. These partnerships have enhanced his research and development endeavors, leading to groundbreaking inventions.

Conclusion

Mark E. Duggan's extensive patent portfolio and collaborations underscore his dedication to innovation in the pharmaceutical industry. His work not only showcases his inventiveness but also highlights the potential impact of his inventions on various medical conditions. As the landscape of medicine evolves, Duggan's contributions stand as a vital part of this progress.